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Currently available drugs for Chagas’ disease are limited
by toxicity and low efﬁcacy in the chronic stage. Posa-
conazole, the most advanced new anti-chagasic drug
candidate, did not fully conﬁrm its initial potential in a
Phase II clinical trial for chronic Chagas’ disease. Given
that posaconazole is highly active against Trypanosoma
cruzi in vitro, and was very well tolerated in clinical trials,
it should not be abandoned. Rather, a combination
therapy may provide a highly promising outlook. Sys-
tems-scale approaches facilitate the hunt for a combina-
tion partner for posaconazole, which acts by blocking
sterol biosynthesis. Mounting evidence suggests the
functional interactions between sterols and sphingoli-
pids in vivo. Here, we propose combining sterol and
sphingolipid biosynthesis inhibitors to advance drug
development in Chagas’ disease.
Chagas’ disease: a global burden and the unmet need
for new drugs
Worldwide, an estimated 7 million–8 million people are
infected with the protozoan parasite Trypanosoma cruzi
[1]. Chagas’ disease is endemic in 21 South American
countries but, as a result of population mobility, also occurs
outside the continent [2]. Chagas’ disease poses a global
challenge due to the lack of safe and effective treatment.
Efforts towards the urgently needed new drugs have cul-
minated in the clinical development of triazolic antifungals
for Chagas’ disease. The most advanced drug candidates
were posaconazole and E1224, a prodrug of ravuconazole.
Unfortunately, although very well tolerated, both com-
pounds failed to meet the high expectations in recent
clinical Phase II trials: they did not cure chronic Chagas’
disease as indicated by the high relapse rates observed
during follow-up. Considering that posaconazole and
E1224 are highly active against T. cruzi and well tolerated
in clinical trials, we propose not to abandon the triazoles
but to ﬁnd a suitable partner for combination therapy.
Combination therapy is an attractive approach because it
may improve treatment efﬁcacy while decreasing the
likelihood of resistance development [3]. Systems biology
aims at revealing interconnections of biological networks
and these works serve as useful resources for rational
identiﬁcation of potential interacting partners for chemo-
therapy. Based on genetic, physical, and functional inter-
actions between sterols and sphingolipids [4] and due to
the synthetic lethality of Saccharomyces cerevisiae double
mutants of sterol and sphingolipid anabolism [5], our
opinion is that inhibitors of sphingolipid biosynthesis
are promising combination partners for posaconazole or
ravuconazole.
Current drugs for the treatment of Chagas’ disease
Chagas’ disease remained without an effective treatment
for several decades after its original description in 1909
[6]. Nifurtimox and benznidazole, discovered over 40 years
ago and still the only available drugs for the speciﬁc
treatment of Chagas’ disease, are limited by toxicity and
low efﬁcacy in the established chronic form of the disease
[7]. These major drawbacks, along with upcoming reports
of resistant T. cruzi [8] and the spread of the disease to
nonendemic countries [2], spurred renewed drug research
and development (R&D) for Chagas’ disease. The triazoles
posaconazole and E1224 were the only candidates to pass
the preclinical phase and enter clinical proof-of-concept
trials. However, the results in Phase II clinical trials were
disappointing. While the parasitemia dropped below de-
tection limit after treatment, 10 months later, most
patients again tested positive for T. cruzi [9]. Either can-
didate was less efﬁcacious than benznidazole. This out-
come is arguably attributable to limited systemic exposure
resulting from the liquid suspension of the drug and sub-
optimal treatment duration [10]. Even so, these results
have aggravated the situation in the already slim Chagas’
portfolio, where the most advanced alternatives to the
triazoles have not yet reached clinical Phase I.
Quo vadis posaconazole?
In 1995, V.M. Girijavallabhan described posaconazole
(SCH 56592) as a novel, orally active, broad-spectrum
antifungal agent [11]. Posaconazole (Nofaxil) was devel-
oped by Schering-Plough and was approved by the US Food
and Drug Administration (FDA) for the treatment of inva-
sive fungal infection in humans in 2006 [12]. Similar to
other triazoles, posaconazole is a potent inhibitor of the
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Cyp450-dependent lanosterol 14a-demethylase (Cyp51) in
yeasts and molds [13]. Inhibition of Cyp51 blocks the
synthesis of ergosterol, which is an essential component
in the cell membrane of fungal pathogens. Accumulation of
methylated sterol precursors and disruption of the close
packing of acyl chains of phospholipids in ergosterol-de-
pleted cell membranes ultimately leads to growth inhibi-
tion of the fungi [14]. Similar to fungi, T. cruzi synthesizes
ergosterol and is sensitive to sterol biosynthesis inhibitors
[15]. Posaconazole exhibited excellent in vitro and in vivo
efﬁcacy against both drug-sensitive and -resistant isolates
[16,17]. Suitable combination partners for posaconazole
might be found in the sterol biosynthesis pathway to
enhance the blockade of this highly interconnected meta-
bolic network. The links between distinct steps of the sterol
biosynthesis pathway can be exempliﬁed in S. cerevisiae: in
the presence of erg6 deletion, the erg2 gene product works
inefﬁciently [4], resulting in an erg6 single deletion mutant
exhibiting a partial phenotype of an erg2erg6 double mu-
tant. Furthermore, cells have evolved compensatory mech-
anisms within metabolic pathways such that accumulating
substrates resulting from inhibition of a speciﬁc enzymatic
step can be alternatively metabolized as a salvage mecha-
nism. Clearly, sterol biosynthesis is of proven druggability
and targeting multiple steps in the same pathway can
potentiate antiparasitic activity. Lovastatin, a blockbuster
used for hypercholesterolemia, enhanced the antiprolifera-
tive effects of ketoconazole and terbinaﬁne against T. cruzi
in vitro and in vivo [18]. Evidence from yeast points in the
same direction because at least a dozen proteins interact-
ing with Erg11 (Cyp51 ortholog in S. cerevisiae) can be
found in the sterol metabolic pathway [19]. Druggable
pathways that interact with sterol metabolism also repre-
sent complementary targets. Glycerophospholipid biosyn-
thesis inhibitors, such as ajoene or alkyl-lysophospholipids
(ALP, e.g., miltefosine), have been shown to have antipro-
liferative effects on T. cruzi epimastigotes and amastigotes
[20–22]. Growth inhibition correlated with a decrease in
the phosphatidylcholine to phosphatidylethanolamine ra-
tio (PC:PE) and, in the case of ALP, also with a marked
effect on sterol composition due to inhibition of sterol 22-
desaturase (Erg5), a ﬁnding that probably explains the
antiproliferative synergism of these drugs with the Cyp51
inhibitor ketoconazole against both proliferative stages
(epimastigotes and intracellular amastigotes) of the para-
site [21,22]. Here, we propose to combine the anti-chagasic
triazoles with inhibitors of sphingolipid synthesis, as sug-
gested by systems approaches.
Systems-based matchmaking
Systems approaches were pioneered in model organisms to
understand how biological systems act as a whole. Emer-
gence of complex behavior is observed when the biological
systems are treated as networks. These can be protein
interaction networks, metabolic networks, or genetic net-
works. All are amenable to large-scale interaction studies,
particularly in S. cerevisiae, where global approaches such
as chemical genetics screens, mutant library screens, pro-
tein–protein interactions, and other -omics technologies
can be automated. These have led to the availability of
databases containing a wealth of information that can be
mined to generate new hypotheses of cellular and system
functions. It can also guide drug discovery in modern
medicine by providing a rational basis to pinpoint interre-
lated pathways. The interacting partners for CYP51 in S.
cerevisiae, for instance, are found on the BioGRID database
[23], containing 103 physical and 184 genetic interactions.
Candidate pathways can be further narrowed by pheno-
types and functionality. Speciﬁcally, interactors of Cyp51
that cause synthetic lethality will be appealing.
Capitalizing on sterol–sphingolipid interactions as a
combinatorial treatment
Posaconazole blocks sterol biosynthesis; thus, druggable
pathways interacting with sterol metabolism and func-
tions represent highly complementary matches for posa-
conazole. Sterols have been shown to modulate membrane
thickness in artiﬁcial membranes and this property has
been proposed to have a role in membrane protein localisa-
tion in vivo [24]. It is increasingly known that proteins and
lipids do not freely diffuse over the entire surface of the cell
and it has been proposed that eukaryotic plasma mem-
branes contain micro- and/or nanodomains (reviewed in
[25–27]) that act as platforms creating membrane hetero-
geneities with many proposed functions. There is clear
biophysical evidence that sterols and sphingolipids can
segregate from other lipids in simple artiﬁcial membrane
systems to form liquid ordered domains [28].
Sterol–sphingolipid interactions have also been demon-
strated in vivo. Evidence in the budding yeast, S. cerevi-
siae, suggests a genetic interaction between mutants in
sterol and sphingolipid biosynthesis [4,5,29,30]. For exam-
ple, mutants that affect the hydroxylation pattern of sphin-
golipids display synthetic growth defects with mutations in
late-acting ergosterol biosynthetic genes [4]. By contrast,
mutations that affect the synthesis of the sphingolipid-
speciﬁc very-long chain C26 fatty acid display strong syn-
thetic lethality with mutations in ERG6, a methyltransfer-
ase that catalyzes the addition of a fungal-speciﬁc methyl
group at position C24 in the aliphatic side chain or ergos-
terol [5]. Figure 1 summarizes experimental evidence on
genetic interactions between the sterol and sphingolipid
synthetic genes. While the bulk of experimental evidence
comes from high throughput screens and needs to be
treated with caution, there is solid support for synthetic
lethality between ELO3 and ERG6 [5], and for synthetic
growth defects of sterol synthetic genes with ISC1, SUR2,
and SCS7 [4]. Strikingly, synthetic lethality has been
demonstrated between CYP51 and SCS7 [31].
In yeast and higher eukaryotes, it has further been shown
that sterols and sphingolipids are important for proper
trafﬁcking of transporters (amino acids and proton pumps)
to the cell surface and their stability at the plasma mem-
brane [32–35]. Adaptation to changes in sterol composition
by adjusting sphingolipid levels and variants is not unique
to the unicellular eukaryotes but is also present in Metazoa,
exempliﬁed by the fruit ﬂy, Drosophila melanogaster. As a
sterol auxotroph, D. melanogaster cannot synthesize sterols
but this lipid is required for larval growth and development.
A drop in sterol levels caused developmental arrest but cells
remain viable, possibly due to a compensatory increase in
sphingolipid levels and composition [36].
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Figure 2 shows the structures of mannosyl diinositol
phosphoryl ceramide [M(IP)2C] and ergosterol, which is
the most abundant sphingolipid and sterol species in yeast.
Together with glycerophospholipids, sterols and sphingo-
lipids comprise the major classes of eukaryotic membrane
lipids. Many membrane characteristics, such as composi-
tion and integrity, turnover or trafﬁcking, and signaling,
fulﬁll the requirements for bona ﬁde drug targets in para-
sites: they must be (i) essential for parasite survival; (ii)
druggable; and (iii) sufﬁciently different from the host.
Indeed, ‘membrane-lipid therapy’ was coined by Pablo
Escriba´ and is deﬁned as the therapeutic approach based
on the regulation of the membrane-lipid composition and
structure to modulate cell functions [37]. In a broader
sense, we think of membrane therapy as interfering with
membranes directly or via curtailing lipid biosynthesis.
While there currently is no evidence in T. cruzi on the
interactions of sterols and sphingolipids, it is intuitive that
the simultaneous inhibition of both sterol and sphingolipid
metabolism will have a major impact on membrane homeo-
stasis. Moreover, there are several lines of evidence that
these lipids have critical roles in trypanosomatids. Endoge-
nous sterols and sphingolipids are required for proliferation
of trypanosomes [38–40]. Interestingly, reduced inositolpho-
sphoceramide (IPC) levels due to inhibition of serine palmi-
toyltransferase (Spt2) in T. brucei have been shown to be
compensated for by increased levels of phosphatidylcholine
and cholesterol, demonstrating a tight interaction of sterol
and sphingolipid homeostasis [41]. As in yeast, IPC rather
than glycerophospholipids is utilized as lipid anchor con-
stituent of glycoproteins and free glycosylinositolphospho-
lipids (GIPLs) in T. cruzi [42]. Furthermore, inhibition of
IPC synthesis impaired T. cruzi differentiation [43].
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Figure 1. Genetic interactions between sterol and sphingolipid biosynthetic genes
in yeast. Only genes for which an interaction has been experimentally documented
are shown. Data are from BioGRID v. 3.2.117 [23]. Green, positive genetic
interaction; red, negative genetic interaction or synthetic growth defect; black,
synthetic lethality; gray, equivocal results from different screens. For gene symbol
definitions, please see Figure 2.
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Figure 2. Structures of ergosterol and the sphingolipid, mannosyl diinositol phosphoryl ceramide [M(IP)2C]. Genes shown encode enzymes that catalyze major steps in
sterol and sphingolipid metabolism, respectively. The list of genes is not exhaustive but based on sterol/sphingolipid interactions (see also Figure 1). For ergosterol: ERG7,
2,3-oxidosqualene cyclase; ERG11, C14 demethylation; ERG25, C4a methyl oxidation; ERG26, C3 decarboxylation; ERG6, C24 methylation; ERG2, C8 isomerization; ERG3, C5
desaturation; ERG5, C22 desaturation; ERG4, C24 reduction. For M(IP)2C: LCB1, serine C-palmitoyltransferase; LCB2, serine C-palmitoyltransferase; TSC10, 3-
dehydrosphinganine reductase; SUR2, long chain base hydroxylase; ELO3, fatty acyl elongase; LAG1, sphingosine N-acyltransferase; AUR1,
phosphatidylinositol:ceramide phosphoinositol transferase; SCS7, fatty acyl hydroxylase; SUR1, mannosylinositol phosphorylceramide (MIPC) synthase; CSG2, MIPC
synthase regulatory subunit; IPT1, inositolphosphotransferase; ISC1, inositol phosphosphingolipid phospholipase C.
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The relation between sterols and sphingolipids, evident
in yeast and the fruit ﬂy, could indicate a potential evolu-
tionarily conserved adaption mechanism for membrane
homeostasis. Thus, concomitant perturbation of these
two classes of lipids may promote synergistic lethality.
Therefore, it will be interesting to test the interactions
between posaconazole or ravuconazole and sphingolipid
inhibitors on T. cruzi focusing on 100% cidality rather than
potential synergism.
Concluding remarks and outstanding questions
Sterile cidality also against nonproliferating trypanosomes
is imperative to Chagas’ disease chemotherapy. To this
aim, three different strategies have been proposed to select
a suitable combination partner for azoles. The partner
could be a drug such as benznidazole, which is 100% cidal
itself and additive in action with posaconazole [44–46]. It
could also be a drug that is not 100% cidal itself but shows
synergistic interaction with posaconazole, such as amio-
darone, amlodipine, or clemastine [46,47]. In addition,
aiming to completely block sterol synthesis, the combina-
tion partner could be another sterol biosynthesis inhibitor
[15,18]. Here, we propose as an additional strategy the
partnership between posaconazole and sphingolipid inhi-
bitors. This is based on the hypothesis that such a combi-
nation will be most effective in disrupting membrane
integrity and functions, which is critical also for quiescent
cells. Exploration of the chemotherapeutic potential of this
proposed partnership will require: (i) systems knowledge of
T. cruzi lipid physiology; (ii) sphingolipid biosynthesis
inhibitors; and (iii) a test for 100% sterile cidality on the
relevant T. cruzi stages.
Currently, there is no evidence that sterols and
sphingolipids functionally interact in T. cruzi. The ad-
vancing technologies for system-scale analyses of genes,
transcripts, proteins, and metabolites (including lipids)
accompanied by high throughput genetic and chemical
screening, will revolutionize our understanding of T. cruzi
biology and identify possible pathways for combination
therapies. Concomitant chemotherapeutic attack of sterol
Table 1. Sphingolipid biosynthesis inhibitors in clinical trials or on the market
Compound name Clinical phase or drug
name (if on the market)
Mechanism of action Indication Refs
N-butyldeoxynojirimycin Miglustat, Zavesca1 Glucosylceramide synthase inhibitor Gaucher disease
FTY720 Gilenya Sphingosine-1-phosphate receptor inhibitor Multiple sclerosis [49]
Saﬁngol Phase I Sphingosine kinase inhibitor Cancer [50]
Phenoxodiol Phase III Sphingosine kinase inhibitor Cancer [51]
ABC294640 Phase I Sphingosine kinase inhibitor Cancer [52]
Sphingomab Preclinical Anti-sphingosine-1-phosphate antibody Cancer [53]
Fenretinide Phase I Ceramide desaturase inhibitor Cancer [54]
Desipramine Treyzafagit, Norpramin,
and Pertofrane
Acid sphingomyelinase inhibitor Antidepressant
Imiglucerase Cerezyme b-glucocerebrosidase replacement Gaucher disease
Amitriptyline Phase IIb Acid sphingomyelinase inhibitor Cystic Fibrosis [55]
Elavil, Endep, and Vanatrip Antidepressant
Analgesic
Fluoxetine ROzac, PROzac Weekly,
Sarafem, Rapiﬂux, Selfemra,
and PROzac Pulvules
Acid sphingomyelinase inhibitor Antidepressant
Aureobasidin Aa Phase I Inositol phosphorylceramide synthase inhibitor Antifungal [56]
aFailed in clinical Phase I.
Table 2. Sterol biosynthesis inhibitorsa
Class Target and/or mechanism of action Indication Refs
Statins Competitive inhibitors of HMG-CoA reductase, preventing the formation of
mevalonate from HMG-CoA; they occupy the HMG-binding pocket and part of
the binding surface for CoA
Used as cholesterol-
lowering drugs in humans
[57,58]
Bisphosphonates (BPs) Potent inhibitors of bone resorption. The selective action on bone is based on
the binding of the BP moiety to the bone mineral; nitrogen-containing BPs bind
to, and inhibit the activity of, farnesyl diphosphate synthase
Used to treat osteoporosis
and other bone resorption
diseases
[59–61]
Quinuclidines and/
or zaragozic acids
Inhibition of squalene synthase (SQS); quinuclidines may inhibit SQS by
acting as carbocation mimics for FPP to squalene conversion. The aryl units
may act as isosteres for the isoprenyl subunits in the farnesyl chain.
Not in clinical use [62]
Allylamines Speciﬁc inhibition of fungal squalene mono-oxygenase Used for topical treatment
of fungal infections
[63,64]
Azoles Bind as the sixth ligand to the haem in lanosterol 14 a-demethylase (= CYP51),
thus occupying the active site and acting as noncompetitive inhibitors;
blocking the synthesis of ergosterol leads to the accumulation of methylated
sterol precursors
Used to treat fungal
infections
[65,66]
Azasterols Evidence from yeast shows that azasterols inhibit the enzyme C24-sterol
methyltransferase
Not in clinical use [67]
aCompound classes of molecule known to interfere with sterol metabolism. Target enzymes and mechanisms of action are indicated, as well as clinical indications where
molecules are already on the market.
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and sphingolipid biosynthesis is facilitated by the avail-
ability of sphingolipid inhibitors [48], owing to the inter-
ests in their functions in human health. As with every drug
candidate, consideration must be given to the potential
toxicity of sphingolipid biosynthesis inhibitors. Toxicity is
one reason why most of the numerous existing sphingoli-
pid inhibitors remain experimental compounds [48]. None-
theless, this class of compounds is promising, because
there are several in clinical use or in clinical trials for a
spectrum of human diseases (Table 1) and, given the role of
sphingolipids in many other human diseases, efforts to
discover novel compounds are ongoing. The same applies
for sterol biosynthesis inhibitors (Table 2). A crucial re-
quirement for R&D of next-generation anti-chagasic
agents will be an in vitro test that is amenable to medium
throughput and that can demonstrate 100% cidality
against nonproliferating intracellular amastigote T.
cruzi. Such an assay must be able to predict the lack of
sterile cidality of posaconazole and ravuconazole.
In summary, we argue that the potential of posacona-
zole must be further explored with a view of rational target
identiﬁcation and achieving combination therapy through
systems-scale approaches. Based on evidence in model
organisms, particularly the budding yeast, the matching
of sphingolipid synthesis inhibitors as partners of triazoles
can impair membrane functionality and, thus, may kill
proliferating as well as dormant parasites.
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